Paucity of PD-L1 Expression in Prostate Cancer: Innate and Adaptive Immune Resistance

BACKGROUND: Primary prostate cancers are infiltrated with PD-1 expressing CD8+ T cells. However, in early clinical trials, men with mCRPC did not respond to PD-1 blockade as a monotherapy. One explanation for this unresponsiveness could be that prostate tumors generally do not express PD-L1, the pri...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Prostate Cancer Prostatic Dis
Egile Nagusiak: Martin, Allison M., Nirschl, Thomas R., Nirschl, Christopher J., Francica, Brian J., Kochel, Christina M., van Bokhoven, Adrie, Meeker, Alan K., Lucia, M. Scott, Anders, Robert A., DeMarzo, Angelo M., Drake, Charles G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4641011/
https://ncbi.nlm.nih.gov/pubmed/26260996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2015.39
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak